ATNX.Q Stock Overview
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Athenex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.015 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$0.0003 |
| Beta | 0.79 |
| 1 Month Change | 52.00% |
| 3 Month Change | -86.19% |
| 1 Year Change | -99.72% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Athenex prices $30M in stock and warrants offering
Aug 11Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal
Aug 05Athenex GAAP EPS, revenue misses estimates
Jul 28Athenex to sell its China API business for $19M
Jul 11Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.
Aug 31Athenex EPS beats by $0.13, beats on revenue
May 06Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?
Apr 04
Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?
Mar 09These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts
Mar 06Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?
Feb 19When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?
Jan 29
Shareholder Returns
| ATNX.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 2.8% |
| 1Y | -99.7% | -3.3% | 24.6% |
Return vs Industry: ATNX.Q underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: ATNX.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| ATNX.Q volatility | |
|---|---|
| ATNX.Q Average Weekly Movement | 339.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ATNX.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ATNX.Q's weekly volatility has increased from 167% to 339% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 275 | Johnson Lau | www.athenex.com |
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company’s Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer.
Athenex, Inc. Fundamentals Summary
| ATNX.Q fundamental statistics | |
|---|---|
| Market cap | US$131.68k |
| Earnings (TTM) | -US$97.98m |
| Revenue (TTM) | US$102.82m |
0.0x
P/S Ratio0.0x
P/E RatioIs ATNX.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATNX.Q income statement (TTM) | |
|---|---|
| Revenue | US$102.82m |
| Cost of Revenue | US$76.12m |
| Gross Profit | US$26.70m |
| Other Expenses | US$124.68m |
| Earnings | -US$97.98m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.31 |
| Gross Margin | 25.97% |
| Net Profit Margin | -95.29% |
| Debt/Equity Ratio | -511.7% |
How did ATNX.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/04 11:24 |
| End of Day Share Price | 2023/10/02 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Athenex, Inc. is covered by 12 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Shao | Credit Suisse |
| Jack Hu | Deutsche Bank |
| Umer Raffat | Evercore ISI |